Pomalidomide experience: an effective therapeutic approach with immunomodulatory drugs in a patient with relapsed-refractory multiple myeloma.

about

Pomalidomide experience: an effective therapeutic approach with immunomodulatory drugs in a patient with relapsed-refractory multiple myeloma.

Item

http://www.wikidata.org/entity/Q38766508

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Pomalidomide experience: an ef ...... d-refractory multiple myeloma.

@en

type

Item

label

Pomalidomide experience: an ef ...... d-refractory multiple myeloma.

@en

prefLabel

Pomalidomide experience: an ef ...... d-refractory multiple myeloma.

@en

P1476

Pomalidomide experience: an ef ...... ed-refractory multiple myeloma

@en

P2093

Alessia La Fauci

http://www.w3.org/2001/XMLSchema#string

Concetta Conticello

http://www.w3.org/2001/XMLSchema#string

Flavia Ancora

http://www.w3.org/2001/XMLSchema#string

Francesco Di Raimondo

http://www.w3.org/2001/XMLSchema#string

Maria Letizia Consoli

http://www.w3.org/2001/XMLSchema#string

Marina Parisi

http://www.w3.org/2001/XMLSchema#string

P2860

The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.

Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.

Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications.

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.

Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma.

Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma.

In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone.

Eribulin in 'field practice': an overview of the Italian experience.

P304

3-6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON-2016-0368

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Alessandra Romano

Valeria Calafiore

P577

2017-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28116941

http://www.w3.org/2001/XMLSchema#string